8-K current report · filed Nov 5, 2026

Keros Therapeutics, Inc. (KROS) 8-K Current Report: November 5, 2026

Item 7.01Item EX-99.1KROS overview

Short answer

Keros Therapeutics, Inc. (KROS) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Updated corporate presentation signals refreshed investor messaging and potentially new company or pipeline information.

Keros Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Updated corporate presentation signals refreshed investor messaging and potentially new company or pipeline information
  • Exhibit 99.1 contains the substantive presentation, available through Keros Therapeutics’ website
  • Investors should review the presentation for changes to clinical, regulatory, cash runway, or strategic outlook disclosures

Item EX-99.1 · Exhibit EX-99.1

  • November 2026 presentation highlights rinvatercept’s expanding pipeline role across DMD and ALS, increasing potential value beyond a single indication
  • Phase 2 DMD basket trial commenced, with initial data expected in first half of 2027
  • ALS Phase 2 design discussions with regulators planned for second half of 2026, creating a near-term clinical catalyst
  • Elritercept partnership with Takeda provides $200M upfront and over $1.1B potential milestones, with three Phase 3 trials underway
  • KER-206 remains nonclinical, with osteoporosis mouse data supporting further development but no human validation yet

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Keros Therapeutics, Inc. 8-K filings

Get the next KROS 8-K as it lands

Follow KROS for push alerts, or ask the research agent what this filing means.